+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

An MRI Evaluation of Patients Who Underwent Treatment with a Cell-Mediated Gene Therapy for Degenerative Knee Arthritis: A Phase IIa Clinical Trial



An MRI Evaluation of Patients Who Underwent Treatment with a Cell-Mediated Gene Therapy for Degenerative Knee Arthritis: A Phase IIa Clinical Trial



Journal of Knee Surgery 30(7): 694-703



Multiple therapies have been developed to slow down the progression of knee osteoarthritis (OA), with the aim of avoiding or delaying TKA. One such potential method is cell-mediated gene therapy, which utilizes allogeneic human chondrocytes modified to express transforming growth factor-β1. Using magnetic resonance imaging (MRI), we evaluated patients who underwent treatment with this injection in a Phase II study and assessed structural changes in: (1) bone marrow edema lesions, (2) cartilage defect depth and surface area, (3) articular bone surface and osteophytes, and (4) meniscus structure and signal, as well as changes in (5) joint fluid, (6) periarticular inflammation, and (7) synovial inflammation. Twenty-seven patients (6 men and 21 women) who had late-stage OA were randomized 1:1 to receive a 3:1 mixture of nontransduced chondrocytes and genetically engineered chondrocytes, at doses of 6 × 106 cells (group 1) or 1.8 × 107 cells (group 2). MRI was performed at baseline (preinjection), and at 6 and 12 months postinjection. The whole-organ MRI score system was used to assess the aforementioned changes. Treatment was considered to be successful if patients experienced an improvement in or no change in their scores, indicating that the disease had not progressed. All patients in both cohorts individually demonstrated an improvement or no change in one or more of the assessment parameters. At 6 months, the low-dose cohort demonstrated worsening in mean scores in one parameter (bone surface and osteophytes), while the high-dose cohort demonstrated no worsening in mean scores. At 12 months, the low-dose cohort had worsening in the mean score in a subset of one parameter (cartilage signal intensity), and the high-dose cohort demonstrated worsening in mean scores in two parameters (bone surface osteophytes and periarticular inflammation). This is the first study to evaluate MRI changes in patients treated with this injection. These findings provide an impetus for further research on this topic, as well as a starting point for Phase III testing.

Accession: 059368887

Download citation: RISBibTeXText

PMID: 27960219

DOI: 10.1055/s-0036-1597275


Related references

A Multicenter, Single-Blind, Phase IIa Clinical Trial to Evaluate the Efficacy and Safety of a Cell-Mediated Gene Therapy in Degenerative Knee Arthritis Patients. Human Gene Therapy. Clinical Development 26(2): 125-130, 2016

Degenerative arthritis of the knee in active patients: evaluation and management. Journal of the American Academy of Orthopaedic Surgeons 7(6): 389-402, 2001

Adenovirus-mediated herpes simplex virus thymidine kinase/ganciclovir gene therapy in patients with localized malignancy: results of a phase I clinical trial in malignant mesothelioma. Human Gene Therapy 9(7): 1083-1092, 1998

Intravitreal autologous bone marrow CD34+ cell therapy for ischemic and degenerative retinal disorders: preliminary phase 1 clinical trial findings. Investigative Ophthalmology & Visual Science 56(1): 81-89, 2015

Arthroscopic treatment of degenerative meniscal lesions and early degenerative arthritis of the knee. Ewing, J W (Ed ) Bristol-Myers/Zimmer Orthopaedic Symposium: Articular Cartilage And Knee Joint Function: Basic Science And Arthroscopy; Meeting, Chicago, Illinois, Usa, November 11-13, 1988 Xxi+369p Raven Press: New York, New York, Usa Illus 137-146, 1990

The effects of extracorporeal shock wave therapy on the pain and function of patients with degenerative knee arthritis. Journal of Physical Therapy Science 29(3): 536-538, 2017

Phase I trial of adenovirus-mediated p53 gene therapy for recurrent glioma: biological and clinical results. Journal of Clinical Oncology 21(13): 2508-2518, 2003

Phase I clinical trial of neoadjuvant adenovirus-mediated HSV-tk gene therapy plus ganciclovir prior to radical prostatectomy. Journal of Urology 163(4 Suppl ): 293, April, 2000

Clinical benefit of 1-year certolizumab pegol (CZP) add-on therapy to methotrexate treatment in patients with early rheumatoid arthritis was observed following CZP discontinuation: 2-year results of the C-OPERA study, a phase III randomised trial. Annals of the Rheumatic Diseases 76(8): 1348-1356, 2017

A phase I/II trial to evaluate the safety, feasibility and activity of salvage therapy consisting of the mTOR inhibitor Temsirolimus added to standard therapy of Rituximab and DHAP for the treatment of patients with relapsed or refractory diffuse large cell B-Cell lymphoma - the STORM trial. Bmc Cancer 13(): 308-308, 2013

The effects of kinesiology taping therapy on degenerative knee arthritis patients' pain, function, and joint range of motion. Journal of Physical Therapy Science 28(1): 63-66, 2016

Recombinant adenoviral-mediated intrapleural gene therapy for malignant mesothelioma Preliminary findings of a Phase I clinical trial. Journal of Investigative Medicine 44(3): 280A, 1996

Clinical versus radiological mid-term results of total knee arthroplasty for degenerative arthritis of the knee. Chirurgia Narzadow Ruchu i Ortopedia Polska 75(5): 296-299, 2011

A phase I clinical trial of an adenovirus-mediated endostatin gene (E10A) in patients with solid tumors. Cancer Biology & Therapy 6(5): 648-653, 2007

Assessment of the value of peat ointment in palliative treatment of patients with rheumatoid arthritis and degenerative disease of knee joints. Reumatologia (Warsaw) 30(1): 43-47, 1992